BACE1 and Alzheimer disease: Several lines of study have revealed NF-κB inhibitors are therapeutically important for treatment of AD pathology because the inhibitors block inflammatory processes and directly inhibit the production of Aβ peptides [19] and NF-κB inhibition prevents Aβ-induced BACE1 promoter transactivation [8,29].